Dosimetric comparison of postoperative interstitial high-dose-rate brachytherapy and modern external beam radiotherapy modalities in tongue and floor of the mouth tumours in terms of doses to critical organs.
HDR
VMAT
brachytherapy
cyberknife
dosimetry
floor of mouth tumour
stereotactic
tongue tumour
Journal
Radiology and oncology
ISSN: 1581-3207
Titre abrégé: Radiol Oncol
Pays: Poland
ID NLM: 9317213
Informations de publication
Date de publication:
01 12 2023
01 12 2023
Historique:
received:
19
05
2023
accepted:
23
08
2023
medline:
4
12
2023
pubmed:
1
12
2023
entrez:
1
12
2023
Statut:
epublish
Résumé
The aim of the study was to dosimetrically compare interstitial high-dose-rate (HDR) brachytherapy (BT) and modern external beam radiotherapy modalities, as volumetric modulated arc therapy (VMAT) and stereotactic radiotherapy with Cyberknife (CK) of tumours of the tongue and floor of the mouth in terms of dose to the critical organs. In National Institute of Oncology, Budapest, between March 2013 and August 2022 twenty patients (11 male/9 female) with stage T1-3N0M0 tongue (n = 14) and floor of mouth (n = 6) tumours received postoperative radiotherapy because of close/positive surgical margin and/or lymphovascular and/or perineural invasion. High-dose-rate interstitial brachytherapy applying flexible plastic catheters with a total dose of 15 × 3 Gy was used for treatment. In addition to BT plans VMAT and stereotactic CK plans were also made in all cases, using the same fractionation scheme and dose prescription. As for the organs at risk, the doses to the mandible, the ipsilateral and the contralateral salivary glands were compared. The mean volume of the planning target volume (PTV) was 12.5 cm The present results confirm that BT, despite being an invasive technique, is dosimetrically clearly beneficial in the treatment of oral cavity tumours and is a modality worth considering when applying radiotherapy, not only as definitive treatment, but also postoperatively. The use of the CK in the head and neck region requires further investigation.
Sections du résumé
BACKGROUND
The aim of the study was to dosimetrically compare interstitial high-dose-rate (HDR) brachytherapy (BT) and modern external beam radiotherapy modalities, as volumetric modulated arc therapy (VMAT) and stereotactic radiotherapy with Cyberknife (CK) of tumours of the tongue and floor of the mouth in terms of dose to the critical organs.
PATIENTS AND METHODS
In National Institute of Oncology, Budapest, between March 2013 and August 2022 twenty patients (11 male/9 female) with stage T1-3N0M0 tongue (n = 14) and floor of mouth (n = 6) tumours received postoperative radiotherapy because of close/positive surgical margin and/or lymphovascular and/or perineural invasion. High-dose-rate interstitial brachytherapy applying flexible plastic catheters with a total dose of 15 × 3 Gy was used for treatment. In addition to BT plans VMAT and stereotactic CK plans were also made in all cases, using the same fractionation scheme and dose prescription. As for the organs at risk, the doses to the mandible, the ipsilateral and the contralateral salivary glands were compared.
RESULTS
The mean volume of the planning target volume (PTV) was 12.5 cm
CONCLUSIONS
The present results confirm that BT, despite being an invasive technique, is dosimetrically clearly beneficial in the treatment of oral cavity tumours and is a modality worth considering when applying radiotherapy, not only as definitive treatment, but also postoperatively. The use of the CK in the head and neck region requires further investigation.
Identifiants
pubmed: 38038418
pii: raon-2023-0050
doi: 10.2478/raon-2023-0050
pmc: PMC10690754
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
516-523Informations de copyright
© 2023 Örs Ferenczi et al., published by Sciendo.
Références
Strnad V. Treatment of oral cavity and oropharyngeal cancer. Indications, technical aspects, and results of interstitial brachytherapy. Strahlenther Onkol 2004; 180: 710–17. doi: 10.1007/s00066-004-9196-x
doi: 10.1007/s00066-004-9196-x
Ferenczi Ö, Major T, Akiyama H, Fröhlich G, Oberna F, Révész M, et al. Results of postoperative interstitial brachytherapy of resectable floor of mouth tumors. Brachytherapy 2021; 20: 376–82. doi: 10.1016/j.brachy.2020.10.008
doi: 10.1016/j.brachy.2020.10.008
Kovács G, Martinez-Monge R, Budrukkar A, Jose Luis G, Bengt J, Vratislav S, et al. GEC-ESTRO ACROP recommendations for head & neck brachytherapy in squamous cell carcinomas: 1st update – Improvement by cross sectional imaging based treatment planning and stepping source technology. Radiother Oncol 2017; 122: 248–54. doi: 10.1016/j.radonc.2016.10.008
doi: 10.1016/j.radonc.2016.10.008
Chinn SB, Myers JN. Oral cavity carcinoma: current management, controversies, and future directions. J Clin Oncol 2015; 33: 3269–76. doi: 10.1200/JCO.2015.61.2929
doi: 10.1200/JCO.2015.61.2929
Mazeron JJ, Ardiet JM, Haie-Méder C, Kovács Gy, Levendag P, Peiffert D, et al. GEC-ESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas. Radiother Oncol 2009; 91: 150–6. doi: 10.1016/j.radonc.2009.01.005
doi: 10.1016/j.radonc.2009.01.005
Ivaldi E, Di Mario D, Paderno A, Piazza C, Bossi P, Nicola Alessandro, et al. Postoperative radiotherapy (PORT) for early oral cavity cancer (pT1-2, N0-1): A review. Crit Rev Oncol Hematol 2019; 143: 67–75. doi: 10.1016/j.critrevonc.2019.08.003
doi: 10.1016/j.critrevonc.2019.08.003
Potharaju M, E Raj H, Muthukumaran M, Venkataraman M, IIangovan B, Kupussam S, et al. Long-term outcome of high-dose-rate brachytherapy and perioperative brachytherapy in early mobile tongue cancer. J Contemp Brachytherapy 2018; 10: 64–72. PMID: 29619058
pubmed: 29619058
Aaboubout Y, Van der Toom QM, de Ridder MAJ, Herdt MJ, Van der Steen B, Van Lanschot GC, et al. Is the depth of invasion a marker for elective neck dissection in early oral squamous cell carcinoma? Front Oncol 2021; 11: 628320. doi: 10.3389/fonc.2021.628320
doi: 10.3389/fonc.2021.628320
Sternick ES, editor. The theory and practice of intensity modulated radiation therapy . 1st edition. Madison WI: Advanced Medical Publishing; 1997.
Grégoire V, De Neve W, Eisbruch A, Lee N, Van den Weyngaert, Van Gestel D, et al. Intensity-modulated radiation therapy for head and neck carcinoma. Oncologist 2007; 12: 555–64. doi: 10.1634/theoncologist.12-5-555
doi: 10.1634/theoncologist.12-5-555
Yu CX, Li XA, Ma L, Chen D, Naqvi S, Shepard D, et al. Clinical implementation of intensity-modulated arc therapy. Int J Radiat Oncol Biol Phys 2002; 53: 453–63. doi: 10.1016/s0360-3016(02)02777-3
doi: 10.1016/s0360-3016(02)02777-3
Osborn J. Is VMAT beneficial for patients undergoing radiotherapy to the head and neck? Radiography 2017; 23: 73–6. doi: 10.1016/j.radi.2016.08.008
doi: 10.1016/j.radi.2016.08.008
Adler JR, Cox RS. Preliminary experience with CyberKnife - Radiosurgery . Basel: S. Karger; 1996. p. 112–38.
Kurup G. CyberKnife: a new paradigm in radiotherapy. J Med Phys 2010; 35: 63–4. doi: 10.4103/0971-6203.62194
doi: 10.4103/0971-6203.62194
Takácsi-Nagy Z, Ferenczi Ö, Major T, Akiyama H, Fröhlich G, Ferenc O, et al. Results of sole postoperative interstitial, high-dose-rate brachytherapy of T1-2 tongue tumours. Strahlenther Onkol 2022; 198: 812–9. doi: 10.1007/s00066-022-01901-w
doi: 10.1007/s00066-022-01901-w
Santos M, Guinot JL, Tortajada M, Vendrell JB, López C, La Rosa A, et al. Is perioperative brachytherapy effective in carcinoma of the tongue? J Contemp Brachytherapy 2022; 14: 23–8. doi: 10.5114/jcb.2022.113425
doi: 10.5114/jcb.2022.113425
Erickson BA, Demanes DJ, Ibbott GS, Hayes JK, Hsu ICJ, Morris DE, et al. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2011; 79: 641–9. doi: 10.1016/j.ijrobp.2010.08.046
doi: 10.1016/j.ijrobp.2010.08.046
Yamazaki H, Yoshida K, Yoshioka Y, Shimizutani K, Furukawa S, Koizumi M, et al. High dose rate brachytherapy for oral cancer. J Radiat Res 2013; 54: 1–17. doi: 10.1093/jrr/rrs103
doi: 10.1093/jrr/rrs103
Union for International Cancer Control, UICC. TNM classification of malignant tumours . 8th Edition. Brierley JD, Gospodarowicz MK, Wittekind C, editors. Wiley Blackwell; 2017.
Baltas D, Kolotas C, Geramani K, Mould RF, Ioannidis G, Kekchidi M, et al. A conformal index (COIN) to evaluate implant quality and dose specification in brachytherapy. Int J Radiat Oncol Biol Phys 1998; 40: 515–24. doi: 10.1016/s0360-3016(97)00732-3
doi: 10.1016/s0360-3016(97)00732-3
ICRU Report 83, Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). Strahlenther Onkol 2012; 188: 97–9. doi: 10.1007/s00066-011-0015-x .
doi: 10.1007/s00066-011-0015-x
Major T, Fröhlich G, Ágoston P, Polgár Cs, Takácsi-Nagy Z. The value of brachytherapy in the age of advanced external beam radiotherapy: a review of the literature in terms of dosimetry. Strahlenther Onkol 2022; 198: 93–109. doi: 10.1007/s00066-021-01867-1
doi: 10.1007/s00066-021-01867-1
Petera J, Sirák I, Laco J, Kašaová L, Tuček L, Doležalová H, et al. High-dose-rate brachytherapy in early oral cancer with close or positive margins. Brachytherapy 2015; 14: 77–83. doi: 10.1016/j.brachy.2014.08.050
doi: 10.1016/j.brachy.2014.08.050
NCCN Clinical Practice Guidelines in Oncology. NCCN Guidelines Version 2.2023, Head and neck cancers. [cited 2023 Apr 15]. Available at: www.nccn.org/guidelines/guidelines-detail?category=1&id=1437
Sresty NVNM, Ramanjappa T, Raju AK, Muralidhar KR, Sudarshan G, et al. Acquisition of equal or better planning results with interstitial brachytherapy when compared with intensity-modulated radiotherapy in tongue cancers. Brachytherapy 2010; 9: 235–8. doi: 10.1016/j.brachy.2009.05.006
doi: 10.1016/j.brachy.2009.05.006
Yoshida K, Takenaka T, Akiyama H, Yamazaki H, Yoshida M, Masui K, et al. Three-dimensional image-based high-dose-rate interstitial brachytherapy for mobile tongue cancer. J Radiat Res 2014; 55: 154–61. doi: 10.1093/jrr/rrt079
doi: 10.1093/jrr/rrt079
Akiyama H, Pesznyák C, Béla D, Ferenczi Ö, Major T, Polgár Cs, et al. Image guided high-dose-rate brachytherapy versus volumetric modulated arc therapy for head and neck cancer: a comparative analysis of dosimetry for target volume and organs at risk. Radiol Oncol 2018; 52: 461–7. doi: 10.2478/raon-2018-0042
doi: 10.2478/raon-2018-0042
Kubota H, Miyawaki D, Mukumoto N, Ishihara T, Matsumura M, Hasegawa T, et al. Risk factors for osteoradionecrosis of the jaw in patients with head and neck squamous cell carcinoma. Radiat Oncol 2021; 16: 1. doi: 10.1186/s13014-020-01701-5
doi: 10.1186/s13014-020-01701-5
Peterson DE, Doerr W, Hovan A, Pinto A, Saunders D, Elting LS, et al. Osteoradionecrosis in cancer patients: the evidence base for treatment-dependent frequency, current management strategies, and future studies. Support Care Cancer 2010; 18: 1089–98. doi: 10.1007/s00520-010-0898-6
doi: 10.1007/s00520-010-0898-6
Swain M, Ghosh-Laskar S. Stereotactic body radiotherapy (SBRT) for primary non-metastatic head and neck cancer: when less is enough. Oral Oncol 2021; 116: 105265. doi: 10.1016/j.oraloncology.2021.105265
doi: 10.1016/j.oraloncology.2021.105265
Jánváry ZL, Ferenczi Ö, Takácsi-Nagy Z, Bajcsay A, Polgár Cs, et al. Application of CyberKnife stereotactic radiosurgery in the treatment of head and neck cancer. Magy Onkol 2018; 62: 180–5.
Biau J, Thivat E, Millardet C, Saroul N, Pham-Dang N, Molnar I, et al. A multicenter prospective phase II study of postoperative hypofractionated stereotactic body radiotherapy (SBRT) in the treatment of early-stage oropharyngeal and oral cavity cancers with high risk margins: the STEREO POSTOP GORTEC 2017-03 trial. BMC Cancer 2020; 20: 730. doi: 10.1186/s12885-020-07231-3
doi: 10.1186/s12885-020-07231-3
Kim MS, Malik NH, Chen H, Poon I, Husain Z, Eskander A, et al. Stereotactic radiotherapy as planned boost after definitive radiotherapy for head and neck cancers: Systematic review. Head and Neck 2022; 44: 770–82. doi: 10.1002/hed.26948
doi: 10.1002/hed.26948
Zhang Y, Chiu T, Dubas J, Tian Z, Lee P, Gu X, et al. Benchmarking techniques for stereotactic body radiotherapy for early-stage glottic laryngeal cancer: LINAC-based non-coplanar VMAT vs . Cyberknife planning. Radiat Oncol 2019; 14: 193. doi: 10.1186/s13014-019-1404-z
doi: 10.1186/s13014-019-1404-z
Owosho AA, Thor M, Oh JH, Riaz N, Tsai CJ, Rosenberg H, et al. The role of parotid gland irradiation in the development of severe hyposalivation (xerostomia) after intensity-modulated radiation therapy for head and neck cancer: Temporal patterns, risk factors, and testing the QUANTEC guidelines. J Craniomaxillofac Surg 2017; 45: 595–600. doi: 10.1016/j.jcms.2017.01.020
doi: 10.1016/j.jcms.2017.01.020